Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.

Here's some of what is coming soon to NeurologyLive® this week.

An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.

Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.

Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.

Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.